Sulzer : Medmix AG launches share offering and sets price range at CHF 37 to CHF 47 per share

• Sulzer's Ltd. shareholders approved the spin-off of medmix AG ("medmix") at the extraordinary shareholders' meeting of Sulzer Ltd ("Sulzer") held on September 20, 2021
• medmix is offering up to 7'000'000 new shares to be issued in a capital increase, targeting gross proceeds of approximately CHF 300 million
• The price range for the offered shares has been set at CHF 37 to CHF 47 per share
• The offer period will commence on September 22, 2021 and is anticipated to end on September 29, 2021
• Start of trading of the existing medmix shares on SIX Swiss Exchange is expected to take place on September 30, 2021, with the offered shares expected to commence trading on October 1, 2021.

The share offering comprises up to 7'000'000 new shares. medmix is targeting gross proceeds of approximately CHF 300 million.

The price range for the offered shares has been set at CHF 37 to CHF 47 per share.

The offering consists of a public offering in Switzerland, and international private placements outside Switzerland in accordance with applicable securities laws.

The offering is intended to fund further growth, increase trading liquidity through a higher free float and introduce new, healthcare-focused investors to medmix. medmix' reference shareholder Tiwel Holding will not participate in the offering, which will increase the free float of medmix.

medmix has agreed to a lock-up period of six months after the settlement of the capital increase in connection with the offering. Furthermore, the company plans to expand its board of directors by proposing at least two additional independent members for election at the AGM in spring 2022.

Credit Suisse AG and UBS AG are acting as exclusive financial advisors to Sulzer in the context of the spin-off.

About medmix

medmix resulted from Sulzer's decision to spin off its Applicator Systems division and separately list it on SIX Swiss Exchange with a view to leveraging the business' full potential as a global market leader in high-precision delivery devices serving the healthcare, industrial and consumer markets and to further accelerate its growth. The spin-off was executed in the form of a symmetrical demerger according to art. 29 para b) and art. 31 para 2a) of the Swiss Merger Act, with Sulzer shareholders receiving one medmix share on or around September 30 for each Sulzer share held on September 29, 2021 after close of trading on SIX Swiss Exchange. The spin-off became legally effective upon registration in the commercial registers of the Cantons of Zurich and Zug simultaneously with the incorporation of medmix AG, following the approval of the transaction by the extraordinary general meeting of Sulzer Ltd on September 20, 2021.